Rüschoff, Josef
Friedrich, Michael
Nagelmeier, Iris
Kirchner, Matthias
Andresen, Lena M.
Salomon, Karin
Portier, Bryce
Sredni, Simone T.
Schildhaus, Hans Ulrich
Jasani, Bharat
Grzelinski, Marius
Viale, Giuseppe
Funding for this research was provided by:
Agilent Technologies
Article History
Received: 31 March 2022
Revised: 30 June 2022
Accepted: 6 July 2022
First Online: 16 August 2022
Declarations
:
: IVD-related diagnostic study is covered by an ethic approval to Agilent Technologies Inc., USA. All methods were performed in accordance with the relevant guidelines and regulations. Data were anonymized prior to use for the study.
: LMA and KS are employees and shareholders of Agilent Technologies Denmark Aps. BP and STS are employees and shareholders by Agilent Technologies Inc., USA. BJ and GV have acted as a consultant for Agilent Technologies Denmark Aps.Honoraria for lectures and advisory boards have been received by JR from MSD/Merck, GSK, BMS, AstraZeneca, Roche, Exact Sciences, QuIP GmbH; HUS from MSD, BMS, Pfizer, Novartis Oncology, Roche Pharma, Molecular Health; GV from Roche, AstraZeneca, MSD, Pfizer, Novartis, Daiichi Sankyo.